LL-37
A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues.
LL-37: A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues. LL-37 is an antimicrobial peptide your innate immune system already makes.
LL-37 is an antimicrobial peptide your innate immune system already makes. People use it for chronic infections, biofilms (bacterial slime that resists antibiotics), and immune support. Strong effect in lab data, less data in humans.
Not prescribed in conventional medicine.
Who it's for
- →Users with chronic biofilm-associated infections
- →Wound-healing contexts
- →Stack add-on for aggressive immune protocols
What to expect
- Week 1
Subtle. Mild flu-like symptoms in first few doses for some users.
- Week 4
Full cycle. Reassess infection markers.
- Week 8
Off-cycle.
Looking at LL-37? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for LL-37.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Cathelicidin-derived antimicrobial peptide (the human cathelicidin family's only member). Disrupts bacterial membranes through pore formation and modulates innate immune signaling.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Mast cell activation syndrome (MCAS)
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • CBC if running long courses
Common mistakes
- • Treating it as a substitute for antibiotics (it's adjunct, not replacement)
- • Pushing dose in MCAS-prone users
- • Skipping the cycle break
What it actually is
LL-37 is the only antimicrobial peptide your body makes in the cathelicidin family, released by skin, gut lining and immune cells as a first-line defence. It punches holes in bacterial membranes directly and also signals to the immune system. Its literature is enormous — over 2,000 papers and 33 randomised trials — but almost all of that is about the peptide your body already makes, not about injecting extra.
The molecule is positively charged and folds into a helix with water-loving and fat-loving faces. Bacterial membranes are more negatively charged than human ones, so LL-37 is drawn to them preferentially, inserts, and disrupts the membrane. Because that is a physical mechanism rather than a metabolic target, resistance is generally thought to arise more slowly than to conventional antibiotics — though bacterial resistance mechanisms against antimicrobial peptides are documented, so slower is a relative claim rather than an absolute one. It also disrupts biofilms and signals to immune cells, and that immune signalling is a double-edged property.
Forms, and which is which
Buyer reconstitutes. Research-chemical supply with unverified identity.
Verdict: The common route, and the one with least evidence behind it.
The route closest to how the endogenous peptide works — locally, at a surface. Most of the therapeutic development has been topical.
Verdict: The most mechanistically coherent route.
Studied for cystic fibrosis and airway infection, where the peptide is naturally deficient.
Verdict: A real research direction, in specific disease.
Vitamin D upregulates cathelicidin gene expression, which is one of the better-understood links between vitamin D status and infection risk. That is not the same as supplementation treating an infection, and excess vitamin D causes hypercalcaemia, kidney injury and arrhythmias.
Verdict: Worth correcting a measured deficiency; not a risk-free lever to pull.
What it is claimed to do, graded
Extensively demonstrated in vitro, including against biofilms that resist conventional antibiotics. This is the peptide's core, well-established property.
Shown in animal models of sepsis and gut injury.
The reason people take it, and no controlled human trial supports systemic injection for this. The trial literature is about endogenous levels and topical or inhaled routes.
The opposite is well documented: LL-37 is implicated in driving inflammation in psoriasis, rosacea and lupus, where too much of it is part of the disease. More is not simply better.
It can trigger mast cell activation, and its role in autoimmune inflammation makes systemic dosing a genuine concern rather than a formality.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • A large, legitimate scientific literature — one of the most-studied antimicrobial peptides
- • Physical membrane mechanism, which is generally thought to select for resistance more slowly than conventional antibiotics
- • Active against biofilms, which conventional antibiotics struggle with
- • Correcting a measured vitamin D deficiency raises your own cathelicidin production, which is a better-grounded route than injecting the peptide
- • The huge paper count is about endogenous LL-37, not about injecting it — the gap is routinely used to oversell it
- • Directly implicated in the pathology of psoriasis, rosacea and lupus
- • Can trigger mast cell activation, which makes it a poor choice in MCAS
- • Very short systemic half-life
- • Research-chemical supply with unverified identity
When to stop
- • Any flare of psoriasis, rosacea or another inflammatory skin condition
- • Flushing, hives, itching or other mast-cell symptoms
- • Flu-like symptoms persisting beyond the first few doses
- • Injection-site reaction that spreads
Interactions
LL-37 is a known mast cell activator. In MCAS this is the wrong direction entirely.
LL-37 is part of the disease mechanism in each of these. Adding more is not a neutral act.
Vitamin D upregulates your own cathelicidin production. Worth correcting a documented deficiency; excess causes hypercalcaemia and kidney injury, so this is not a dose-it-higher lever.
Different mechanism, and the biofilm activity is complementary in principle. Untested as a combination in people.
Opposing effects on immune signalling.
Is this for you?
- • People considering the topical route for a local problem, with realistic expectations
- • Anyone who would rather raise their own levels by fixing vitamin D status
- • You have mast cell activation syndrome
- • You have psoriasis, rosacea or lupus — LL-37 is part of the mechanism in all three
- • You are pregnant or nursing
- • You are expecting the huge paper count to be evidence for injecting it
The one number
Sources for the claims above
- Preserves intestinal barrier and organ function in a sepsis model
- Multifunctional roles including in heart disease
- Upregulating expression as a preventive strategy
Drug & supplement interactions
- ⚠Mast cell activation syndrome (MCAS): may worsen, avoid
- ⚠Limited documented interactions
New to LL-37? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about LL-37 or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is LL-37?+
Is LL-37 FDA approved?+
Is LL-37 legal?+
Is LL-37 banned by WADA?+
Are you still natty after taking LL-37?+
Do doctors prescribe LL-37?+
What's the typical dose of LL-37?+
What are the side effects of LL-37?+
How long until LL-37 starts working?+
What can you stack with LL-37?+
Where do people get LL-37?+
LL-37 vs Thymosin Alpha-1 (Tα1), which is better?+
Common questions about LL-37
Head-to-head with LL-37
Tracked alongside LL-37
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Immune
Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.
Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker.
Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation.
Used to rebuild a weakened immune system, mainly in older or post-illness patients. A polypeptide complex extracted from calf thymus and distinct from Thymosin Alpha-1, used in Russian and Eastern European clinical practice for immune restoration in elderly patients and post-illness recovery.